PubMed COVID-19 Clinical Care

Vaccines to protect against human papillomavirus (HPV) infection are recommended for all adolescents by the World Health Organization (WHO) and are primarily delivered in school-based settings. This systematic review aims to summarize the available

No abstract

CONCLUSIONS: PWH with low CD4 T-cell counts had worse COVID-19 outcomes compared to people without HIV, but outcomes for those with high CD4 counts were similar to, or better than, those without HIV. It is unclear whether these findings are

CONCLUSION: Our findings suggest that the capacity of the Chinese healthcare system was adequate to face the Omicron XBB wave in spring 2023 but, at the same time, supports the importance of administering highly effective vaccine with long-lasting

CONCLUSIONS: Although HPV vaccines have been available for more than 15 years, global HPV vaccination coverage is low. During the covid-19 pandemic period (2020-21 globally), worsening coverage, delayed introductions of national vaccine programmes

Since 2020, cases of COVID-19-associated pulmonary aspergillosis (CAPA) have been frequently described, representing an important cause of mortality, especially among patients admitted to intensive care unit (ICU). A predisposition to invasive

[This corrects the article DOI: 10.1093/pnasnexus/pgac200.].

[This corrects the article DOI: 10.1093/pnasnexus/pgac031.].

[This corrects the article DOI: 10.1093/pnasnexus/pgac218.].

[This corrects the article DOI: 10.1093/pnasnexus/pgac045.].